Graham J, Earnshaw S, Lim J, Luthra R, Borker R. Cost-effectiveness of afatinib versus erlotinib in the first-line treatment of patients with metastatic non-small cell lung cancer with EGFR Exon 19 deletion mutations. JCP. 2016 May;2(4):31-9.
Samsell B, Moore M, Bertasi G, Spinato S, Bernardello F, Rebaudi A, Sfasciotti GL, Powers R. Are bone allografts safe and effective for today's dental practitioner? Dentistry. 2014 Nov 3;4(9):1000260. doi: 10.4172/2161-1122.1000260